INKON Life(SZ:300143) EBSCN·2025-08-26 03:43Investment Rating - The report maintains a "Buy" rating for the company [5] Core Viewpoints - The medical services segment continues to expand, with a revenue of 6.53 billion yuan in the first half of 2025, reflecting a year-on-year growth of 2.28%. The oncology business is a key driver, achieving a revenue of 2.15 billion yuan, up 25.14% year-on-year [2] - The medical device segment shows robust growth in international markets, with a revenue of 1.90 billion yuan, a year-on-year increase of 2.80%. The overseas revenue grew by 35% due to the addition of 9 new distributors [2] - The acquisition of a 51% stake in Changsha Kexin Oncology Hospital is expected to enhance the company's oncology specialty and further boost the performance of the medical services segment [3] Financial Performance Summary - In the first half of 2025, the company achieved a total revenue of 843 million yuan, a year-on-year increase of 2.40%. The net profit attributable to shareholders was 62 million yuan, up 12.82% year-on-year, and the net profit excluding non-recurring items was 61 million yuan, reflecting a growth of 19.22% [1] - The projected net profit for 2025 is estimated at 139 million yuan, with corresponding EPS of 0.19 yuan [3] Revenue and Profit Forecast - The company forecasts revenues of 1.905 billion yuan for 2025, with a growth rate of 22.15%. The net profit is projected to reach 139 million yuan, with a growth rate of 20.66% [4][9]